Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanocort pilot study in active Graves' orbitopathy
NL-OMON24926Phase 2Active, not recruiting
- Sponsor
- Het Oogziekenhuis Rotterdam
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of hydrocortisone in Graves' ophthalmopathy (TED), sponsored by Het Oogziekenhuis Rotterdam. Started Nov 2017; status: active, not recruiting.
02
Drugs
hydrocortisone
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on NL-OMON24926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24926.